Brought to you by 
Bellicum nets $149mm in initial public offering
01 Dec 2017
Executive Summary
Bellicum Pharmaceuticals Inc. (cellular immunotherapies for cancer and immune and blood disorders) netted $149mm in its IPO of 8.4mm shares (including the overallotment) for $19; it had planned for 6.25mm shares at $15-17. Some investors indicated an interest in buying $50mm of the IPO shares.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Bellicum nets $149mm in initial public offering
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice